Xeris Biopharma (XERS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

XERS Stock Forecast

Xeris Biopharma stock forecast is as follows: an average price target of $5.28 (represents a 75.42% upside from XERS’s last price of $3.01) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

XERS Price Target

The average price target for Xeris Biopharma (XERS) is $5.28 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $6.60 to $3.00. This represents a potential 75.42% upside from XERS's last price of $3.01.

XERS Analyst Ratings

Buy

According to 5 Wall Street analysts, Xeris Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for XERS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Xeris Biopharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 11, 2024	Oren Livnat	H.C. Wainwright	$6.60	$3.25	103.39%	119.27%
Oct 23, 2024	Leland Gershell	Oppenheimer	$5.00	$3.02	65.56%	66.11%
May 10, 2024	David Amsellem	Piper Sandler	$3.00	$1.85	62.43%	-0.33%
Apr 28, 2022	-	Craig-Hallum	$6.50	$2.33	178.97%	115.95%

Row per page

Go to

The latest Xeris Biopharma stock forecast, released on Nov 11, 2024 by Oren Livnat from H.C. Wainwright, set a price target of $6.60, which represents a 103.39% increase from the stock price at the time of the forecast ($3.25), and a 119.27% increase from XERS last price ($3.01).

Xeris Biopharma Price Target by Period

	1M	3M	12M
# Anlaysts	2	2	3
Avg Price Target	$5.80	$5.80	$4.87
Last Closing Price	$3.01	$3.01	$3.01
Upside/Downside	92.69%	92.69%	61.79%

In the current month, the average price target of Xeris Biopharma stock is $5.80, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 92.69% increase as opposed to Xeris Biopharma's last price of $3.01. This month's average price target is down 0.00% compared to last quarter, and up 19.10% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 11, 2024	H.C. Wainwright	Buy	Buy	Hold
Nov 11, 2024	Piper Sandler	Overweight	Neutral	Downgrade
Oct 23, 2024	Oppenheimer	Outperform	Outperform	Hold
Aug 09, 2024	Craig-Hallum	Buy	Buy	Hold
May 10, 2024	Piper Sandler	Overweight	Overweight	Hold
Apr 28, 2022	Craig-Hallum	-	Buy	Initialise
Jan 02, 2022	SVB Leerink	Outperform	Outperform	Hold

Row per page

Go to

Xeris Biopharma's last stock rating was published by H.C. Wainwright on Nov 11, 2024. The company gave XERS a "Buy" rating, the same as its previous rate.

Xeris Biopharma Financial Forecast

Xeris Biopharma Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
Revenue	-	-	-	-	-	-	-	-	$44.39M	$48.32M	$38.01M	$33.20M	$33.14M	$29.73M	$25.31M	$22.07M	$21.67M	$11.04M	$8.91M	$8.05M	$7.17M	$9.45M	$2.03M	$1.79M	$1.83M	$323.00K	$320.00K	$248.00K	$819.00K
Avg Forecast	$65.10M	$62.77M	$58.43M	$53.67M	$55.99M	$51.45M	$45.84M	$41.81M	$43.17M	$40.64M	$35.16M	$31.03M	$30.96M	$29.04M	$25.46M	$23.39M	$18.97M	$11.02M	$9.68M	$7.17M	$8.78M	$4.46M	$1.90M	$1.40M	$660.40K	$50.00K	$50.00K	$75.00K	$1.10M
High Forecast	$68.16M	$65.72M	$61.18M	$56.54M	$58.08M	$51.48M	$45.84M	$41.81M	$45.20M	$40.64M	$36.81M	$32.49M	$32.42M	$29.04M	$25.46M	$23.39M	$18.97M	$11.02M	$9.68M	$7.17M	$8.78M	$4.46M	$1.90M	$1.40M	$660.40K	$50.00K	$50.00K	$75.00K	$1.32M
Low Forecast	$60.88M	$58.70M	$54.65M	$50.79M	$51.60M	$51.41M	$45.84M	$41.81M	$40.37M	$40.64M	$32.88M	$29.02M	$28.96M	$29.04M	$25.46M	$23.39M	$18.97M	$11.02M	$9.68M	$7.17M	$8.78M	$4.46M	$1.90M	$1.40M	$660.40K	$50.00K	$50.00K	$75.00K	$877.82K
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	9	13	8	8	9	12	7	7	8	16
Surprise %	-	-	-	-	-	-	-	-	1.03%	1.19%	1.08%	1.07%	1.07%	1.02%	0.99%	0.94%	1.14%	1.00%	0.92%	1.12%	0.82%	2.12%	1.07%	1.28%	2.77%	6.46%	6.40%	3.31%	0.75%

Xeris Biopharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $41.81M, with a low forecast of $41.81M, and a high forecast of $41.81M. XERS's average Quarter revenue forecast represents a -5.80% decrease compared to the company's last Quarter revenue of $44.39M (Dec 23).

Xeris Biopharma EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	9	13	8	8	9	12	7	7	8	16
EBITDA	-	-	-	-	-	-	-	-	$-9.84M	$-4.91M	$-15.98M	$-10.57M	$-12.46M	$-16.07M	$-15.66M	$-25.97M	$-48.09M	$-23.89M	$-25.40M	$-16.28M	$-16.82M	$-13.29M	$-21.65M	$-27.36M	$-31.63M	$-28.99M	$-33.10M	$-24.08M	$-12.35M
Avg Forecast	$-49.13M	$-47.37M	$-44.10M	$-40.50M	$-42.26M	$-38.83M	$-34.60M	$-31.56M	$-32.58M	$-30.67M	$-26.53M	$-23.42M	$-23.37M	$-20.20M	$-17.71M	$-16.27M	$-13.20M	$-7.67M	$-6.73M	$-18.20M	$-6.11M	$-3.10M	$-1.32M	$-27.36M	$-459.37K	$-34.78K	$-34.78K	$-15.68M	$-16.54M
High Forecast	$-45.95M	$-44.30M	$-41.24M	$-38.33M	$-38.94M	$-38.80M	$-34.60M	$-31.56M	$-30.47M	$-30.67M	$-24.81M	$-21.90M	$-21.85M	$-20.20M	$-17.71M	$-16.27M	$-13.20M	$-7.67M	$-6.73M	$-14.56M	$-6.11M	$-3.10M	$-1.32M	$-21.89M	$-459.37K	$-34.78K	$-34.78K	$-12.55M	$-13.23M
Low Forecast	$-51.44M	$-49.60M	$-46.17M	$-42.67M	$-43.84M	$-38.85M	$-34.60M	$-31.56M	$-34.11M	$-30.67M	$-27.78M	$-24.52M	$-24.47M	$-20.20M	$-17.71M	$-16.27M	$-13.20M	$-7.67M	$-6.73M	$-21.84M	$-6.11M	$-3.10M	$-1.32M	$-32.84M	$-459.37K	$-34.78K	$-34.78K	$-18.82M	$-19.85M
Surprise %	-	-	-	-	-	-	-	-	0.30%	0.16%	0.60%	0.45%	0.53%	0.80%	0.88%	1.60%	3.64%	3.12%	3.77%	0.89%	2.75%	4.28%	16.37%	1.00%	68.85%	833.55%	951.67%	1.54%	0.75%

undefined analysts predict XERS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Xeris Biopharma's previous annual EBITDA (undefined) of $NaN.

Xeris Biopharma Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	9	13	8	8	9	12	7	7	8	16
Net Income	-	-	-	-	-	-	-	-	$-13.39M	$-12.19M	$-19.84M	$-26.61M	$-12.93M	$-21.83M	$-26.18M	$-33.71M	$-52.59M	$-26.01M	$-27.52M	$-18.41M	$-21.86M	$-16.00M	$-24.10M	$-29.18M	$-33.08M	$-32.84M	$-34.38M	$-25.28M	$-12.99M
Avg Forecast	$-1.99M	$-3.97M	$-6.95M	$-10.43M	$-9.45M	$-12.91M	$-14.45M	$-15.79M	$-12.74M	$-15.58M	$-17.13M	$-23.47M	$-22.15M	$-22.95M	$-32.14M	$-36.10M	$-31.15M	$-50.81M	$-44.50M	$-20.58M	$-55.48M	$-76.84M	$-108.59M	$-29.18M	$-168.22M	$-182.09M	$-139.44M	$-16.46M	$-17.40M
High Forecast	$-1.82M	$-3.64M	$-6.37M	$-6.52M	$-4.72M	$-11.83M	$-13.23M	$-14.46M	$-9.91M	$-14.27M	$-15.69M	$-21.49M	$-20.28M	$-22.95M	$-32.14M	$-36.10M	$-31.15M	$-50.81M	$-44.50M	$-16.46M	$-55.48M	$-76.84M	$-108.59M	$-23.35M	$-168.22M	$-182.09M	$-139.44M	$-13.17M	$-13.92M
Low Forecast	$-2.11M	$-4.22M	$-7.38M	$-13.04M	$-11.81M	$-13.70M	$-15.33M	$-16.76M	$-18.40M	$-16.53M	$-18.18M	$-24.90M	$-23.50M	$-22.95M	$-32.14M	$-36.10M	$-31.15M	$-50.81M	$-44.50M	$-24.69M	$-55.48M	$-76.84M	$-108.59M	$-35.02M	$-168.22M	$-182.09M	$-139.44M	$-19.76M	$-20.88M
Surprise %	-	-	-	-	-	-	-	-	1.05%	0.78%	1.16%	1.13%	0.58%	0.95%	0.81%	0.93%	1.69%	0.51%	0.62%	0.89%	0.39%	0.21%	0.22%	1.00%	0.20%	0.18%	0.25%	1.54%	0.75%

Xeris Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XERS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Xeris Biopharma SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	9	13	8	8	9	12	7	7	8	16
SG&A	-	-	-	-	-	-	-	-	$37.57M	$37.29M	$37.63M	$33.60M	$34.36M	$34.49M	$32.98M	$35.91M	$54.18M	$26.54M	$25.93M	$18.93M	$18.00M	$16.48M	$17.64M	$21.61M	$20.64M	$14.88M	$15.02M	$12.52M	$4.50M
Avg Forecast	$124.78M	$120.30M	$112.00M	$102.86M	$107.32M	$98.61M	$87.87M	$80.15M	$82.75M	$77.90M	$67.38M	$59.48M	$59.35M	$55.67M	$48.81M	$44.84M	$36.37M	$21.13M	$18.55M	$13.74M	$16.82M	$8.55M	$3.64M	$2.68M	$1.27M	$95.83K	$95.83K	$143.75K	$2.10M
High Forecast	$130.65M	$125.96M	$117.27M	$108.38M	$111.33M	$98.67M	$87.87M	$80.15M	$86.64M	$77.90M	$70.55M	$62.28M	$62.14M	$55.67M	$48.81M	$44.84M	$36.37M	$21.13M	$18.55M	$13.74M	$16.82M	$8.55M	$3.64M	$2.68M	$1.27M	$95.83K	$95.83K	$143.75K	$2.52M
Low Forecast	$116.70M	$112.51M	$104.75M	$97.35M	$98.89M	$98.54M	$87.87M	$80.15M	$77.39M	$77.90M	$63.02M	$55.63M	$55.50M	$55.67M	$48.81M	$44.84M	$36.37M	$21.13M	$18.55M	$13.74M	$16.82M	$8.55M	$3.64M	$2.68M	$1.27M	$95.83K	$95.83K	$143.75K	$1.68M
Surprise %	-	-	-	-	-	-	-	-	0.45%	0.48%	0.56%	0.56%	0.58%	0.62%	0.68%	0.80%	1.49%	1.26%	1.40%	1.38%	1.07%	1.93%	4.84%	8.07%	16.31%	155.24%	156.77%	87.08%	2.14%

Xeris Biopharma's average Quarter SG&A projection for Mar 24 is $80.15M, based on 1 Wall Street analysts, with a range of $80.15M to $80.15M. The forecast indicates a 113.34% rise compared to XERS last annual SG&A of $37.57M (Dec 23).

Xeris Biopharma EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18
# Analysts	1	1	1	2	5	4	1	1	2	1	1	1	1	1	1	1	1	1	1	9	13	8	8	9	12	7	7	8	16
EPS	-	-	-	-	-	-	-	-	$-0.00	$-0.09	$-0.00	$-0.19	$-0.10	$-0.16	$-0.19	$-0.25	$-0.43	$-0.39	$-0.41	$-0.30	$-0.41	$-0.35	$-0.63	$-0.89	$-1.23	$-1.22	$-1.28	$-1.07	$-3.07
Avg Forecast	$-0.01	$-0.03	$-0.05	$-0.07	$-0.06	$-0.09	$-0.10	$-0.11	$-0.09	$-0.10	$-0.12	$-0.16	$-0.15	$-0.15	$-0.22	$-0.24	$-0.21	$-0.34	$-0.30	$-0.34	$-0.37	$-0.52	$-0.73	$-0.88	$-1.13	$-1.23	$-0.94	$-0.76	$-1.18
High Forecast	$-0.01	$-0.02	$-0.04	$-0.04	$-0.03	$-0.08	$-0.09	$-0.10	$-0.07	$-0.10	$-0.11	$-0.14	$-0.14	$-0.15	$-0.22	$-0.24	$-0.21	$-0.34	$-0.30	$-0.34	$-0.37	$-0.52	$-0.73	$-0.88	$-1.13	$-1.23	$-0.94	$-0.76	$-0.94
Low Forecast	$-0.01	$-0.03	$-0.05	$-0.09	$-0.08	$-0.09	$-0.10	$-0.11	$-0.12	$-0.11	$-0.12	$-0.17	$-0.16	$-0.15	$-0.22	$-0.24	$-0.21	$-0.34	$-0.30	$-0.34	$-0.37	$-0.52	$-0.73	$-0.88	$-1.13	$-1.23	$-0.94	$-0.76	$-1.41
Surprise %	-	-	-	-	-	-	-	-	0.00%	0.84%	0.00%	1.21%	0.64%	1.03%	0.88%	1.03%	2.05%	1.14%	1.37%	0.87%	1.10%	0.68%	0.86%	1.01%	1.08%	0.99%	1.36%	1.41%	2.60%

According to undefined Wall Street analysts, Xeris Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XERS previous annual EPS of $NaN (undefined).

Xeris Biopharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
ELEV	Elevation Oncology	$0.58	$9.00	1451.72%	Buy
XFOR	X4 Pharmaceuticals	$0.37	$3.67	891.89%	Buy
INZY	Inozyme Pharma	$2.81	$14.67	422.06%	Buy
PDSB	PDS Bio	$2.10	$9.00	328.57%	Buy
DAWN	Day One Biopharmaceuticals	$13.52	$38.80	186.98%	Buy
TERN	Terns Pharmaceuticals	$5.91	$14.25	141.12%	Buy
MREO	Mereo BioPharma Group	$3.49	$6.75	93.41%	Buy
MCRB	Seres Therapeutics	$0.69	$1.25	81.16%	Buy
XERS	Xeris Biopharma	$3.01	$5.28	75.42%	Buy
CDTX	Cidara Therapeutics	$15.63	$24.00	53.55%	Buy
IBRX	ImmunityBio	$5.35	$8.00	49.53%	Buy
HOOK	HOOKIPA Pharma	$2.79	$3.00	7.53%	Buy
EFTR	eFFECTOR Therapeutics	-	$5.50	-	Buy

XERS Forecast FAQ

Is Xeris Biopharma a good buy?

Yes, according to 5 Wall Street analysts, Xeris Biopharma (XERS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of XERS's total ratings.

What is XERS's price target?

Xeris Biopharma (XERS) average price target is $5.28 with a range of $3 to $6.6, implying a 75.42% from its last price of $3.01. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Xeris Biopharma stock go up soon?

According to Wall Street analysts' prediction for XERS stock, the company can go up by 75.42% (from the last price of $3.01 to the average price target of $5.28), up by 119.27% based on the highest stock price target, and down by -0.33% based on the lowest stock price target.

Can Xeris Biopharma stock reach $5?

XERS's average twelve months analyst stock price target of $5.28 supports the claim that Xeris Biopharma can reach $5 in the near future.

What is Xeris Biopharma's current price target trend?

2 Wall Street analysts forecast a $5.8 price target for Xeris Biopharma (XERS) this month, up 92.69% from its last price of $3.01. Compared to the last 3 and 12 months, the average price target increased by 92.69% and increased by 61.79%, respectively.

What are Xeris Biopharma's analysts' financial forecasts?

Xeris Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $195.1M (high $197.22M, low $190.67M), average EBITDA is $-147M (high $-144M, low $-149M), average net income is $-52.605M (high $-44.247M, low $-57.605M), average SG&A $373.94M (high $378.02M, low $365.45M), and average EPS is $-0.353 (high $-0.297, low $-0.387). XERS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $239.97M (high $251.61M, low $225.02M), average EBITDA is $-181M (high $-170M, low $-190M), average net income is $-23.342M (high $-18.344M, low $-26.739M), average SG&A $459.94M (high $482.25M, low $431.3M), and average EPS is $-0.157 (high $-0.123, low $-0.179).

Did the XERS's actual financial results beat the analysts' financial forecasts?

Based on Xeris Biopharma's last annual report (Dec 2023), the company's revenue was $163.91M, beating the average analysts forecast of $150M by 9.28%. Apple's EBITDA was $-44.01M, missing the average prediction of $-113M by -61.12%. The company's net income was $-62.255M, missing the average estimation of $-68.92M by -9.67%. Apple's SG&A was $146.1M, missing the average forecast of $287.51M by -49.19%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.463 by -99.89%. In terms of the last quarterly report (Dec 2023), Xeris Biopharma's revenue was $44.39M, beating the average analysts' forecast of $43.17M by 2.82%. The company's EBITDA was $-9.841M, missing the average prediction of $-32.581M by -69.80%. Xeris Biopharma's net income was $-13.39M, beating the average estimation of $-12.738M by 5.12%. The company's SG&A was $37.57M, missing the average forecast of $82.75M by -54.60%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.0855 by -99.88%